drugset / Trial / NCT04899921
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.
Timeline
- Start
- 2021-06-30
- Primary completion
- 2023-05-29
- Completion
- 2023-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Troriluzole | Peptide | 140 mg | Oral |
| Subject | Troriluzole | Peptide | 280 mg | Oral |
| Subject | Troriluzole | Peptide | 420 mg | Oral |
| Background | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Nivolumab | Monoclonal antibody | 1 mg/kg | Intravenous |